HR positive

P2, N=976, Recruiting, MedSIR | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Dec 2028 --> Jun 2028

P=N/A, N=200, Completed, University College Cork | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026

Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.

Notably, GPR30 inhibition attenuated MEHP-induced promotion of MCF-7 cell proliferation and migration through modulating of EMT process.

These data support T-DXd as a broadly efficacious treatment for patients with HR+, HER2-low/-ultralow mBC after ≥1 ET, regardless of TTP on prior first-line ET + CDK4/6i, endocrine resistance, or disease burden.

TFF3 is a robust diagnostic biomarker for BRCA molecular subtyping, an independent prognostic factor, and a potential immunomodulator. These findings highlight its clinical utility for patient stratification and potential as a therapeutic target, particularly in hormone receptor-positive BRCA.

This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.

P1/2, N=174, Active, not recruiting, Monte Rosa Therapeutics, Inc | Recruiting --> Active, not recruiting

Patients receiving chemotherapy following ET had limited benefit from available treatments, highlighting unmet treatment needs in this population.

P=N/A, N=81, Not yet recruiting, University Hospital, Grenoble

Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.

In asymptomatic patients at recurrence, the first distant recurrence was detected significantly earlier using imaging modalities than using blood tests. Conclusion Symptom status at first distant breast cancer recurrence may be associated with post-recurrence survival, with asymptomatic recurrence showing more favorable outcomes.